From epidemiology to pathophysiology: What about caffeine in Alzheimer's disease?

Biochemical Society Transactions

Volumn 42, Issue 2, 2014, Pages 587-592

  Flaten, Vanessa ^a,b   Laurent, Cyril ^a,b   Coelho, Joana E ^c   Sandau, Ursula ^d   Batalha, Vânia L ^c   Burnouf, Sylvie ^a,b,e   Hamdane, Malika ^a,b,c   Humez, Sandrine ^a,b   Boison, Detlev ^d   Lopes, Luísa V ^c   Buée, Luc ^a,b,f   Blum, David ^a,b,f  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d LEGACY RESEARCH   (United States)

^e MAX PLANCK INSTITUTE FOR BIOLOGY OF AGEING   (Germany)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Caffeine; Epidemiology

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; AMYLOID BETA PROTEIN; BETA SECRETASE 1; CAFFEINE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; INSULINASE; PRESENILIN 1; RYANODINE RECEPTOR; TAU PROTEIN; ADENOSINE RECEPTOR BLOCKING AGENT;

AGING; ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIET; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; CAFFEINE; HUMANS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1;

EID: 84897012511     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20130229     Document Type: Review

References (74)

1. Reitz, C., Brayne, C. and Mayeux, R. (2011) Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7, 137-152
2. Pasinetti, G.M. and Eberstein, JA. (2008) Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J. Neurochem. 106, 1503-1514
3. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D. and Jones, E. (2011) Alzheimer's disease. Lancet 377, 1019-1031
4. Leboucher, A., Laurent, C., Fernandez-Gomez, F.J., Burnouf, S., Troquier, L., Eddarkaoui, S., Demeyer, D., Caillierez, R., Zommer, N., Vallez, E. et al. (2013) Detrimental effects of diet-induced obesity on tau pathology are independent of insulin resistance in tau transgenic mice. Diabetes 62, 1681-1688
5. La Rue, A. (2010) Healthy brain aging: role of cognitive reserve, cognitive stimulation, and cognitive exercises. Clin. Geriatr. Med. 26, 99-111
6. Belarbi, K., Burnouf, S., Fernandez-Gomez, F.J., Laurent, C., Lestavel, S., Figeac, M., Sultan, A., Troquier, L., Leboucher, A., Caillierez, R. et al. (2011) Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like tau pathology. Neurobiol. Dis. 43, 486-494
7. Checler, F. (1995) Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem. 65, 1431-1444
8. De Strooper, B., Vassar, R. and Golde, T. (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99-107
9. 1-42 oligomers are revealed in vivo by using a novel animal model. J. Neurosci. 32, 7852-7861
10. Buée, L., Bussiere, T., Buée-Scherrer, V., Delacourte, A. and Hof, P.R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130
11. Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E. et al. (2008) Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 5, 207-224 (Pubitemid 351670926)
12. Sultan, A., Nesslany, F., Violet, M., Begard, S., Loyens, A., Talahari, S., Mansuroglu, Z., Marzin, D., Sergeant, N., Humez, S. et al. (2011) Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem. 286, 4566-4575
13. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Abraham, R., Hamshere, M.L., Pahwa, J.S., Moskvina, V. et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435
14. Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wolfing, H., Chieng, B.C., Christie, M.J., Napier, I.A. et al. (2010) Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142, 387-397
15. Vingtdeux, V., Sergeant, N. and Buée, L. (2012) Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. Front. Physiol. 3, 229
16. Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., Carlson, G.A., Lanier, L.M., Yuan, L.L. et al. (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067-1081
17. Polydoro, M., Acker, C.M., Duff, K., Castillo, P.E. and Davies, P. (2009) Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 29, 10741-10749
18. Van der Jeugd, A., Ahmed, T., Burnouf, S., Belarbi, K., Hamdame, M., Grosjean, M.E., Humez, S., Balschun, D., Blum, D., Buée, L. and D'Hooge, R. (2011) Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol. Learn. Mem. 95, 296-304
19. Van der Jeugd, A., Vermaercke, B., Derisbourg, M., Lo, A.C., Hamdane, M., Blum, D., Buée, L. and D'Hooge, R. (2013) Progressive age-related cognitive decline in tau mice. J. Alzheimer's Dis. 37, 777-778
20. Lo, AC, Iscru, E., Blum, D., Tesseur, I., Callaerts-Vegh, Z., Buée, L., De Strooper, B., Balschun, D. and D'Hooge, R. (2013) Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer's disease. J. Alzheimer's Dis. 37, 109-125
21. Burnouf, S., Martire, A., Derisbourg, M., Laurent, C., Belarbi, K., Leboucher, A., Fernandez-Gomez, F.J., Troquier, L., Eddarkaoui, S., Grosjean, M.E. et al. (2013) NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a tau transgenic model. Aging Cell 12, 11-23
22. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S., Younkin, S. et al. (2013) TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127
23. Heneka, M.T. and O'Banion, M.K. (2007) Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184, 69-91 (Pubitemid 46365992)
24. Wyss-Coray, T. and Rogers, J. (2012) Inflammation in Alzheimer disease: a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2, a006346
25. Fredholm, B.B., Battig, K., Holmen, J., Nehlig, A. and Zvartau, E.E. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51, 83-133 (Pubitemid 29113867)
26. Haskell, C.F., Kennedy, D.O., Wesnes, K.A. and Scholey, A.B. (2005) Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology 179, 813-825 (Pubitemid 40767901)
27. Riedel, W., Hogervorst, E., Leboux, R., Verhey, F., van Praag, H. and Jolles, J. (1995) Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 122, 158-168 (Pubitemid 26019151)
28. Lorist, M.M. and Tops, M. (2003) Caffeine, fatigue, and cognition. Brain Cogn. 53, 82-94 (Pubitemid 37311280)
29. Takahashi, R.N., Pamplona, F.A. and Prediger, R.D. (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front. Biosci. 13, 2614-2632
30. van Gelder, B.M., Buijsse, B., Tijhuis, M., Kalmijn, S., Giampaoli, S., Nissinen, A. and Kromhout, D. (2007) Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur. J. Clin. Nutr. 61, 226-232
31. Ritchie, K., Carriere, I., de Mendonca, A., Portet, F., Dartigues, J.F., Rouaud, O., Barberger-Gateau, P. and Ancelin, M.L. (2007) The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 69, 536-545 (Pubitemid 47357260)
32. Maia, L. and de Mendonca, A. (2002) Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 9, 377-382 (Pubitemid 35013893)
33. Lindsay, J., Laurin, D., Verreault, R., Hebert, R., Helliwell, B., Hill, G.B. and McDowell, I. (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 156, 445-453 (Pubitemid 34976983)
34. Eskelinen, M.H., Ngandu, T., Tuomilehto, J., Soininen, H. and Kivipelto, M. (2009) Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J. Alzheimer's Dis. 16, 85-91
35. Cao, C., Loewenstein, D.A., Lin, X., Zhang, C., Wang, L., Duara, R., Wu, Y., Giannini, A., Bai, G., Cai, J. et al. (2012) High blood caffeine levels in MCI linked to lack of progression to dementia. J. Alzheimer's Dis. 30, 559-572
36. Gelber, R.P., Petrovitch, H., Masaki, K.H., Ross, G.W. and White, L.R. (2011) Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J. Alzheimer's Dis. 23, 607-615
37. Ross, G.W. and Petrovitch, H. (2001) Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 18, 797-806 (Pubitemid 34073125)
38. Simonin, C., Duru, C., Salleron, J., Hincker, P., Charles, P., Delval, A., Youssov, K., Burnouf, S., Azulay, J.P., Verny, C. et al. (2013) Association between caffeine intake and age at onset in Huntington's disease. Neurobiol. Dis. 58, 179-182
39. Arendash, G.W., Schleif, W., Rezai-Zadeh, K., Jackson, E.K., Zacharia, L.C., Cracchiolo, J.R., Shippy, D. and Tan, J. (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience 142, 941-952 (Pubitemid 44740473)
40. Arendash, G.W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tane, J., Citron, B.A., Lin, X. et al. (2009) Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer's disease mice. J. Alzheimer's Dis. 17, 661-680
41. Prasanthi, J.R., Dasari, B., Marwarha, G., Larson, T., Chen, X., Geiger, J.D. and Ghribi, O. (2010) Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic. Biol. Med. 49, 1212-1220
42. Dostal, V., Roberts, C.M. and Link, C.D. (2010) Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of β-amyloid peptide toxicity. Genetics 186, 857-866
43. Trinh, K., Andrews, L., Krause, J., Hanak, T., Lee, D., Gelb, M. and Pallanck, L. (2010) Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. J. Neurosci. 30, 5525-5532
44. Currais, A., Kato, K., Canuet, L., Ishii, R., Tanaka, T., Takeda, M. and Soriano, S. (2011) Caffeine modulates tau phosphorylation and affects Akt signaling in postmitotic neurons. J. Mol. Neurosci. 43, 326-332
45. 2A receptor deletion in a transgenic model of Alzheimer's disease-like tau pathology. Neuroscience 2013 Meeting, San Diego, CA, U.S.A. 9-13 November 2013, Abstract 523.14/H3
46. 2A receptors in the hippocampus: pharmacological implications. CNS Neurol. Disord. Drug Targets 11, 652-663
47. 2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. NeuroReport 6, 1583-1588
48. 2A adenosine receptors in the hippocampus and cortex of young adult and old rats. J. Neurophysiol. 82, 3196-3203
49. 2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. Neuroscience 133, 79-83
50. Diogenes, M.J., Costenla, A.R., Lopes, L.V., Jeronimo-Santos, A., Sousa, V.C., Fontinha, B.M., Ribeiro, J.A. and Sebastiao, A.M. (2011) Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology 36, 1823-1836
51. 2A receptors in the brain. Neurobiol. Learn. Mem. 87, 42-56 (Pubitemid 44755268)
52. 2A receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol. Psychiatry 18, 320-331
53. Lopes, L.V., Sebastiao, A.M. and Ribeiro, J.A. (2011) Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr. Top. Med. Chem. 11, 1087-1101
54. 2A receptor blockade of β-amyloid neurotoxicity. Br. J. Pharmacol. 138, 1207-1209
55. 2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 203, 241-245
56. Cunha, G.M., Canas, P.M., Melo, C.S., Hockemeyer, J., Muller, C.E., Oliveira, C.R. and Cunha, R.A. (2008) Adenosine A2A receptor blockade prevents memory dysfunction caused by β-amyloid peptides but not by scopolamine or MK-801. Exp. Neurol. 210, 776-781
57. 2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by β-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci. 29, 14741-14751
58. Hasko, G., Pacher, P., Vizi, E.S. and Illes, P. (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol. Sci. 26, 511-516 (Pubitemid 41338561)
59. 2A receptor mediates microglial process retraction. Nat. Neurosci. 12, 872-878
60. 2A receptors control the amyloid-β peptide-induced decrease of glutamate uptake. J. Alzheimer's Dis. 31, 555-567
61. Hindley, S., Herman, M.A. and Rathbone, M.P. (1994) Stimulation of reactive astrogliosis in vivo by extracellular adenosine diphosphate or an adenosine A2 receptor agonist. J. Neurosci. Res. 38, 399-406 (Pubitemid 24209429)
62. 2a receptor induced gliosis via Akt/NF-κB pathway in vitro. Neurosci. Res. 65, 280-285
63. 2a adenosine receptors. J. Pharmacol. Sci. 94, 100-102
64. Pignataro, G., Maysami, S., Studer, F.E., Wilz, A., Simon, R.P. and Boison, D. (2008) Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism. J. Cereb. Blood Flow Metab. 28, 17-23
65. 2A receptor stimulation potentiates nitric oxide release by activated microglia. J. Neurochem. 95, 919-929
66. 2a-receptors. Glia 18, 152-160
67. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 63, 338-346
68. 2A receptor regulation of neuroinflammation and traumatic brain injury. J. Neurosci. 30, 5802-5810
69. 2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J. Neurochem. 117, 100-111
70. Silva, C.G., Métin, C., Fazeli, W., Machado, N.J., Darmopil, S., Launay, P.S., Ghestem, A., Nesa, M.P., Bassot, E., Szabó, E. et al. (2013) Adenosine receptor antagonists including caffeine alter fetal brain development in mice. Sci. Transl. Med. 5, 197ra04
71. Postuma, R.B., Lang, A.E., Munhoz, R.P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Rios Romenets, S., Altman, R. et al. (2012) Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 79, 651-658
72. 2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr. Pharm. Des. 14, 1475-1489
73. 2A receptors and Parkinson's disease. Handb. Exp. Pharmacol. 589-615
74. 2A receptor antagonists for Parkinson's disease. Expert Opin. Invest. Drugs 18, 1619-1631